NO20081075L - Macrocykliske inhibitorer av hepatitt C virus - Google Patents

Macrocykliske inhibitorer av hepatitt C virus

Info

Publication number
NO20081075L
NO20081075L NO20081075A NO20081075A NO20081075L NO 20081075 L NO20081075 L NO 20081075L NO 20081075 A NO20081075 A NO 20081075A NO 20081075 A NO20081075 A NO 20081075A NO 20081075 L NO20081075 L NO 20081075L
Authority
NO
Norway
Prior art keywords
alkylene
alkyl
carbocyclyl
hydrogen
heterocyclyl
Prior art date
Application number
NO20081075A
Other languages
English (en)
Inventor
Herman Augustinus De Kock
Hans Wallberg
Pierre Jean-Marie Raboisson
Kenneth Alan Simmen
Lili Hu
Karl Magnus Nilsson
Bengt Bertil Samuelsson
Asa Annicka Kristina Rosenquist
Anna Karin Gertrud Linnea Belfrage
Mats Stefan Lindstrom
Pia Cecilia Kahnberg
Karin Charlotta Lindquist
Horst Juergen Wahling
Sven Christer Sahlberg
Bjorn Olof Classon
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081075(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20081075L publication Critical patent/NO20081075L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med formel I: og N-oksider, salter, og stereoisomerer derav hvori A er OR1, NHS(=O)pR2; hvori; R1 er hydrogen, C1-C6alkyl, C0-C3alkylenkarbosyklyl, C0-C3alkylenheterosyklyl; R2 er C1-C6alkyl, C0-C3alkylenkarbosyklyl, C0-C3alkylenheterosyklyl; p er uavhengig 1 eller 2; n er 3, 4, 5 eller 6; ----- betegner en eventuell dobbelbinding; L er N eller CRz; Rz er H eller danner en dobbelbinding med karbonet som bærer en stjerne; Rq er H eller når L er CRz, kan Rq også være C1-C6alkyl; Rr er quinazolinyl, eventuelt substituert med én, to eller tre substituenter hver uavhengig valgt fra C1-C6 alkyl, C1-C6alkoksy, hydroksyl, halo, haloC1-C6alkyl, amino, mono- eller dialkylamino, mono- eller dialkylaminokarbonyl, C1-C6alkylkarbonylamino, C0-C3alkylenkarbosyklyl og C0-C3 alkylenheterosyklyl; R5 er hydrogen, C1-C6alkyl, C1-C6alkoksyC1-C6alkyl eller C3-C7sykloalkyl; R6 er hydrogen, C1-C6alkyl, C1-C6alkoksy, C0-C3alkylenkarbosyklyl, C0-C3alkylenheterosyklyl, hydroksy, bromo, kloro eller fluoro har anvendelse ved behandling eller profilakse av flavivirale infeksjoner slik som HCV
NO20081075A 2005-07-29 2008-02-29 Macrocykliske inhibitorer av hepatitt C virus NO20081075L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05107057 2005-07-29
EP06113097 2006-04-25
PCT/EP2006/064822 WO2007014927A2 (en) 2005-07-29 2006-07-28 Macrocyclic inhibitors of hepatitis c virus

Publications (1)

Publication Number Publication Date
NO20081075L true NO20081075L (no) 2008-04-25

Family

ID=37708968

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081075A NO20081075L (no) 2005-07-29 2008-02-29 Macrocykliske inhibitorer av hepatitt C virus

Country Status (31)

Country Link
US (1) US7659245B2 (no)
EP (1) EP1912981B1 (no)
JP (1) JP5230418B2 (no)
KR (1) KR101083631B1 (no)
AP (1) AP2585A (no)
AR (1) AR057702A1 (no)
AT (1) ATE455775T1 (no)
AU (1) AU2006274866B2 (no)
BR (1) BRPI0614153A2 (no)
CA (1) CA2617103C (no)
CY (1) CY1110008T1 (no)
DE (1) DE602006011905D1 (no)
DK (1) DK1912981T3 (no)
EA (1) EA014188B1 (no)
ES (1) ES2339702T3 (no)
GT (1) GT200600343A (no)
HR (1) HRP20100209T1 (no)
IL (1) IL188320A (no)
ME (1) ME01454B (no)
MY (1) MY151026A (no)
NO (1) NO20081075L (no)
NZ (1) NZ564540A (no)
PE (1) PE20070343A1 (no)
PL (1) PL1912981T3 (no)
PT (1) PT1912981E (no)
RS (1) RS51227B (no)
SI (1) SI1912981T1 (no)
SV (1) SV2008002641A (no)
TW (1) TWI387597B (no)
UY (1) UY29704A1 (no)
WO (1) WO2007014927A2 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
PL1713822T3 (pl) 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
TW200745061A (en) 2005-07-29 2007-12-16 Tibotec Pharm Ltd Macrocylic inhibitors of hepatitis C virus
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
ES2356776T3 (es) 2005-10-11 2011-04-13 Intermune, Inc. Compuestos y métodos para inhibir la replicación del virus de la hepatitis.
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2008152171A (ru) 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US7935670B2 (en) 2006-07-11 2011-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PT2041156E (pt) 2006-07-13 2014-02-21 Achillion Pharmaceuticals Inc Péptidos 4-amino-4-oxobutanoil como inibidores da replicação viral
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0718798A2 (pt) * 2006-11-17 2013-12-03 Tibotec Pharm Ltd Inibidores macrocíclicos de vírus da hepatite c
DE602008001251D1 (de) * 2007-02-01 2010-06-24 Tibotec Pharm Ltd Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv
CN101641349A (zh) * 2007-02-08 2010-02-03 泰博特克药品有限公司 嘧啶取代的大环抑制剂
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
WO2009042668A2 (en) * 2007-09-24 2009-04-02 Achillion Pharmaceuticals, Inc. Urea-containing peptides as inhibitors of viral replication
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
US8426360B2 (en) * 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009070692A1 (en) 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009084695A1 (ja) 2007-12-28 2009-07-09 Carna Biosciences Inc. ２－アミノキナゾリン誘導体
CN102015652A (zh) 2008-03-20 2011-04-13 益安药业 作为丙型肝炎病毒抑制剂的氟化大环化合物
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2364309B1 (en) 2008-12-10 2014-10-01 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PL2401272T3 (pl) 2009-02-27 2017-06-30 Janssen Pharmaceuticals, Inc. Amorficzna sól makrocyklicznego inhibitora HCV
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
NZ596546A (en) * 2009-05-29 2012-12-21 Syngenta Participations Ag Substituted quinazolines as fungicides
EP2461811B1 (en) 2009-08-05 2016-04-20 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
EP2658859A4 (en) 2010-12-30 2014-07-30 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6170944B2 (ja) 2011-12-28 2017-07-26 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｈｃｖ阻害剤としてのヘテロ−二環式誘導体
ES2664050T3 (es) * 2012-10-15 2018-04-18 Albemarle Corporation Procesos para la síntesis de la 2-amino-4,6-dimetoxibenzamida y otros compuestos de benzamida
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
AU2003223602B8 (en) 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
CA2515216A1 (en) * 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
ES2320771T3 (es) * 2003-04-16 2009-05-28 Bristol-Myers Squibb Company Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c.
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
RS20060197A (sr) * 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
PL1713822T3 (pl) * 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
RU2419619C2 (ru) * 2005-07-29 2011-05-27 Медивир Аб Макроциклические ингибиторы вируса гепатита с
US8012939B2 (en) * 2005-07-29 2011-09-06 Tibotec Pharmaceuticals Ltd. Co Macrocyclic inhibitors of hepatitis C virus
CN101273042B (zh) * 2005-07-29 2013-11-06 泰博特克药品有限公司 丙型肝炎病毒的大环抑制剂
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c

Also Published As

Publication number Publication date
ES2339702T3 (es) 2010-05-24
IL188320A0 (en) 2008-04-13
CA2617103A1 (en) 2007-02-08
RS51227B (sr) 2010-12-31
NZ564540A (en) 2010-03-26
ME01454B (me) 2014-04-20
TW200745116A (en) 2007-12-16
HRP20100209T1 (hr) 2010-05-31
EP1912981B1 (en) 2010-01-20
PT1912981E (pt) 2010-04-16
IL188320A (en) 2014-07-31
DK1912981T3 (da) 2010-05-25
PE20070343A1 (es) 2007-05-12
CA2617103C (en) 2015-01-06
PL1912981T3 (pl) 2010-07-30
ATE455775T1 (de) 2010-02-15
AP2585A (en) 2013-02-04
CY1110008T1 (el) 2015-01-14
DE602006011905D1 (de) 2010-03-11
JP2009502890A (ja) 2009-01-29
AR057702A1 (es) 2007-12-12
KR20080033475A (ko) 2008-04-16
BRPI0614153A2 (pt) 2011-03-15
KR101083631B1 (ko) 2011-11-16
EA014188B1 (ru) 2010-10-29
JP5230418B2 (ja) 2013-07-10
EP1912981A2 (en) 2008-04-23
EA200800482A1 (ru) 2008-06-30
US20090118312A1 (en) 2009-05-07
SI1912981T1 (sl) 2010-05-31
WO2007014927A3 (en) 2007-11-29
HK1116488A1 (en) 2008-12-24
TWI387597B (zh) 2013-03-01
AU2006274866B2 (en) 2012-04-12
UY29704A1 (es) 2007-05-31
GT200600343A (es) 2007-08-06
SV2008002641A (es) 2008-07-23
AU2006274866A1 (en) 2007-02-08
WO2007014927A2 (en) 2007-02-08
US7659245B2 (en) 2010-02-09
MY151026A (en) 2014-03-31

Similar Documents

Publication Publication Date Title
NO20081075L (no) Macrocykliske inhibitorer av hepatitt C virus
NO20080879L (no) HCV-NS3-proteaseinhibitorer
NO20090595L (no) Ny pyridazinforbindelse og anvendelse derav
TNSN07252A1 (en) Indole derivatives for treating viral infections
IN2012DN00999A (no)
MX2012007420A (es) Analogos para el tratamiento o prevencion de infecciones de flavivirus.
MX337050B (es) Compuestos 4'-azido-nucleósidos como anti-vhc.
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
PE20090478A1 (es) Compuestos de indol macrociclicos como inhibidores de la proteasa del virus de la hepatitis c
MY140729A (en) Amide derivatives
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
NO20090270L (no) Cinnamoyl-piperazinederivater og deres anvendelse som PAR-I-antagonister
NZ593111A (en) Antibacterial compounds
NO20071144L (no) Middel for a tilveiebringe substrater basert pa cellulose og/eller stivelse med vannfrastotende og samtidig soppdrepende, antibakterielle, insektfrastotende og algemotvirkende egenskaper
NO20063407L (no) Benzenforbindelser disubstituert med cykliske grupper i 1- og 2-posisjoner
MY140868A (en) Amide derivatives
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
TW200640879A (en) Amide derivatives
NO20053570L (no) Termostabilt, vannopploselig polymer som er tverrbindbar ved hoye temperaturer
WO2008042497A3 (en) Benzoxazole and benzothiazole compounds useful as authentication compounds in polymer articles
NO20084804L (no) Disazosyre-fargestoffer
TW200728291A (en) Amide derivatives
NO20076389L (no) Sammenstninger og metoder for behandling av HIV-infeksjon med cupredoxin og cytokrom C
CO5630031A2 (es) Derivados de benzotiazol como ligandos del receptor adenosina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application